Drug Trial Radar · NCT07447297
Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
520
Planned (sponsor's estimate)
Start
Jan 2, 2024
Primary completion
Dec 15, 2027
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Samsung Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Korea University Guro Hospital; Korea University Anam Hospital; Keimyung University Dongsan Medical Center; Severance Hospital; Wonju Severance Christian Hospital; Asan Medical Center; Inje University Ilsan Paik Hospital; The Catholic University of Korea
- First posted
- Mar 3, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study to find out the efficacy of early rhythm therapy in patients with subclinical atrial fibrillation detected by Cardiac Electronic Implantable Devices. Early rhythm therapy includes antiarrhythmic drug, cardioversion, and catheter ablation. The general control group receives general management without the above atrial fibrillation rhythm control treatment. Researchers will compare early rhythm control groups to general control groups to see if early rhythm therapy works to reduce the atrial fibrillation burden by 50% or more, or decrease the incidence of clinical AF documentation. Participants will: * Randomly allocated to two groups at a 1:1 ratio. * Receive the treatment according to their assigned group. * Visit the clinic once every three months for checkups and tests.
Conditions
- Atrial Fibrillation (AF)
- Diseases of the Circulatory System
- Atrial Flutter
Interventions
early rhythm control groupDrug
flecainide, propafenone, pilsicainide, sotalol, amiodarone, dronedarone and so on
cardioversion, catheter ablationProcedure
only when clinical atrial fibrillation (if atrial fibrillation continued for more than 30 seconds on a 12-lead electrocardiogram or holter monitoring) is confirmed
general controlOther
General management without atrial fibrillation rhythm control treatment.(Observation without additional medication, or heart rate control treatment if necessary) Heart rate control drugs such as beta-blockers, calcium channel blockers (Non-dihydropyridine CCB), and digoxin are used for heart rate control according to the doctor's prescription.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Less than 50% reduction in atrial fibrillation(AF) burden or clinical AF documentation Incidence Rate (AF recurrence rate)Time frame: From enrollment to 1 year
- side effects related to medication or other treatmentsTime frame: From enrollment to 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Samsung Medical Center
Seoul, Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.